ICCM News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IC

Mkt Cap

$5.0M

Volume

100.51K

Next Earnings

November 18th

Loading chart

IC

ICCMIceCure Medical Ltd. Ordinary Shares

ICCM

Pay with—

Available Balance0.00

IC

Mkt Cap

$4.8M

Volume

100.50K

Next Earnings

November 18th

Chart Financials Earnings News About Insider Filings

IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional InvestorIceCure Medical Ltd. (NASDAQ: ICCM) announced a $5.5 million private placement of 1.83 million ordinary shares and warrants priced at $3.00 per share, representing a premium to the previous closing price. The offering is expected to close on June 18, 2026, with proceeds intended for working capital and general corporate purposes. The company also agreed to amend previously issued warrants to reduce their exercise price from $16.50 to $3.00 per share, subject to shareholder approval.Benzinga · Jun 17, 2026

IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA ClearanceIceCure Medical reported a 70% increase in its U.S. active commercial install base for ProSense® breast cancer cryoablation systems following FDA marketing authorization in October 2025. The growth is driven by FDA clearance, clinical guideline support from the American Society of Breast Surgeons, increased physician demand demonstrated at major medical conferences, and growing patient awareness through media coverage. The company believes it is in the early stages of a significant commercial opportunity in the U.S. market.Benzinga · Jun 17, 2026

IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class OverbookedIceCure Medical announced positive clinical data for its ProSense® cryoablation system at ECIO 2026, showing 89.4% recurrence-free rate for kidney tumors ≤3 cm and 100% excellent cosmetic outcomes in breast cancer patients. The company also reported 92.9% fibroadenoma volume reduction at 12 months. A dedicated breast cryoablation course was held for the first time at the conference, highlighting growing clinical validation and commercial interest in the technology.Benzinga · May 19, 2026

IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid RequirementIceCure Medical Ltd. (NASDAQ: ICCM) has been granted an additional 180-day compliance period until November 9, 2026 to regain compliance with Nasdaq's minimum $1.00 bid price requirement. The company failed to meet the requirement during the first 180-day period ending May 11, 2026, and may implement a reverse share split to cure the deficiency.Benzinga · May 13, 2026

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North AmericaIceCure Medical reported Q1 2026 results with global revenue growth of 26% to $911,000 and North America sales up 84%. Following FDA clearance for breast cancer treatment, active U.S. customer accounts increased 46% to 19 accounts. The company is expanding its U.S. sales footprint to eight regions and expects its ChoICE post-marketing study to accelerate adoption. However, net loss widened to $4.3 million and cash decreased to $8.1 million.Benzinga · May 12, 2026

IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. MarketIceCure Medical showcased its ProSense® cryoablation system at the American Society of Breast Surgeons 2026 Annual Meeting in Seattle. The company reported U.S. revenue for ProSense® systems and cryoprobes increased more than 30% in Q1 2026 compared to Q1 2025. ProSense® is the only FDA-cleared minimally invasive treatment for low-risk breast cancer and has been included in the ASBrS Resource Guide as a recommended treatment option.Benzinga · May 5, 2026

IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free RatesIceCure Medical announced positive results from its ICESECRET clinical trial of ProSense® cryoablation system for treating small renal masses in kidney cancer patients. The study of 112 patients showed an 83.9% recurrence-free rate at median 4-year follow-up, with 89.4% recurrence-free rate in the subgroup of patients with tumors ≤3 cm and no prior kidney cancer. Full results will be presented at the European Conference on Interventional Oncology in April 2026.Benzinga · Mar 25, 2026

IceCure Appoints Meir Peleg as Chief Financial OfficerIceCure Medical (NASDAQ: ICCM) announced the appointment of Meir Peleg as Chief Financial Officer effective May 17, 2026. Peleg brings over 20 years of financial leadership experience with public companies and capital markets expertise. The company also plans to appoint Dr. Richard Fine as Medical Director to lead breast indications. These appointments come as IceCure experiences strong commercial momentum for its ProSense® cryoablation system following FDA clearance for low-risk breast cancer treatment.Benzinga · Mar 24, 2026

IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026IceCure Medical Ltd. (NASDAQ: ICCM), a developer of minimally-invasive cryoablation technology for tumor destruction, announced it will release its 2025 full-year financial and operating results on March 17, 2026, before market open, followed by a conference call at 11:00 a.m. EDT.Benzinga · Mar 10, 2026

American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast CancerThe American Society of Breast Surgeons updated its 2026 Resource Guide to recommend cryoablation as a treatment option for selected patients with biologically low-risk early-stage breast cancer. IceCure Medical's ProSense® cryoablation system, which received FDA clearance in October 2025 for treating low-risk breast cancer in patients aged 70 and above, is positioned to benefit from this clinical endorsement and expected acceleration in commercial adoption.Benzinga · Mar 9, 2026

to start trading

IC

ICCMIceCure Medical Ltd. Ordinary Shares

ICCM

Pay with—

Available Balance0.00

Your PositionYou don't own any ICCM yet.

Related Tickers

Earnings